Aprepitant Helps Prevent Chemotherapy-Induced Nausea, Vomiting

Share this content:
Adding aprepitant to ondansetron is effective in preventing CINV in pediatric patients.
Adding aprepitant to ondansetron is effective in preventing CINV in pediatric patients.

Adding aprepitant to ondansetron with or without dexamethasone is effective in preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric patients undergoing emetogenic chemotherapy, according to a study published in The Lancet Oncology.

In a final analysis of a phase 3 randomized study, Hyoung Jin Kang, MD, and fellow researchers examined patients aged 6 months to 17 years with a documented malignancy who were scheduled to receive either moderately or highly emetogenic chemotherapy.

They were randomly assigned to either aprepitant or control at 49 sites in 24 countries.

RELATED: Non-NK1 Receptor Antagonists Effective Against Chemotherapy-Induced Nausea and Vomiting

The researchers found that 77 out of 152 patients (51 percent0 receiving aprepitant achieved a complete response in the delayed phase, compared to 39 of 150 patients (26 percent) in the control group.

Adverse events in the aprepitant compared to the control group were febrile neutropenia (15 percent vs. 14%), anemia (9 percent vs. 17 percent), and decreased neutrophil count (7% vs. 11%), respectively. 

Reference

  1. Kang, Hyoung Jin, MD, et al. "Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial." The Lancet Oncology. DOI: http://dx.doi.org/10.1016/S1470-2045(15)70061-6. March 11, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters